Overview
2000Founded1
- Tickeron Amsterdam Stock Exchange1
- HeadquartersAmsterdam1
- Websitewww.avantium.com
- Legal formnaamloze vennootschap1
- Listed onAmsterdam Stock Exchange (AVTX), Euronext Brussels (AVTX)1
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Income tax100¢$165.0K
Out of $59.0K in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues, net | $59.0K | $441.0K |
| Cost of product sales | $0 | -$366.0K |
| Research and development | $50.1M | $24.4M |
| Acquired in-process research and development | $0 | $27.6M |
| General and administrative | $22.9M | $17.2M |
| Total operating expenses | $73.0M | $69.0M |
| Loss from operations | -$72.9M | -$68.5M |
| Change in fair value of derivative liability | -$9.5M | -$2.9M |
| Interest income, net | $4.4M | $3.3M |
| Excess of initial warrant fair value over private placement proceeds | $0 | -$79.3M |
| Change in fair value of warrant liability | $0 | $121.6M |
| Private placement transaction costs | $0 | -$9.2M |
| Total other (expense) income, net | -$5.2M | $33.5M |
| Loss before income taxes | -$78.1M | -$35.0M |
| Income tax expense | $165.0K | $114.0K |
| Net loss | -$78.3M | -$35.1M |
| Net loss per share of common stock - basic (in dollars per share) | -$5.84 | -$7.94 |
| Net loss per share of common stock - diluted (in dollars per share) | -$5.84 | -$20.91 |
| Weighted average common shares outstanding - basic (in shares) | 13.4M shares | 4.4M shares |
| Weighted average common shares outstanding - diluted (in shares) | 13.4M shares | 7.5M shares |
| Unrealized income on investments, net | $68.0K | $0 |
| Comprehensive loss | -$78.2M | -$35.1M |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $15.9M | $134.5M | |
| Short-term investments | $82.5M | $0 | |
| Prepaid expenses and other current assets | $6.9M | $4.3M | |
| Restricted cash, current portion | $37.0K | $19.0K | |
| Total current assets | $105.3M | $138.9M | |
| Property and equipment, net | $460.0K | $1.2M | |
| Goodwill | $10.5M | $10.5M | |
| Restricted cash, net of current portion | $210.0K | $131.0K | |
| Total assets | $116.5M | $150.7M | |
| Accounts payable | $137.0K | $283.0K | |
| Accrued expenses and other current liabilities | $12.8M | $6.3M | |
| Derivative liability, current | $0 | $360.0K | |
| Total current liabilities | $12.9M | $7.0M | |
| Royalty obligation | $2.0M | $2.0M | |
| Deferred tax liability, net | $434.0K | $270.0K | |
| Derivative liability, non-current | $18.0M | $8.1M | |
| Other long-term liabilities | $35.0K | $350.0K | |
| Total liabilities | $33.4M | $17.7M | |
| Temporary equity, values issued | $0 | $0 | $0 |
| Common stock$0.001 par value; 200,000,000 shares authorized at December 31, 2025 and December 31, 2024; 18,512,757 and 10,471,934 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $18.0K | $10.0K | |
| Additional paid-in capital | $531.5M | $503.3M | |
| Accumulated other comprehensive income | $68.0K | $0 | |
| Accumulated deficit | -$448.5M | -$370.3M | |
| Total stockholders equity | $83.0M | $133.0M | $7.3M |
| Total liabilities, mezzanine equity and stockholders equity | $116.5M | $150.7M | |
| Temporary equity, shares outstanding (in shares) | 2 shares | 2 shares | 0 shares |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares issued (in shares) | 18.5M shares | 10.5M shares | |
| Common stock, shares outstanding (in shares) | 18.5M shares | 10.5M shares | |
| Preferred stock, par value (in dollars per share) | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 5.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$78.3M | -$35.1M |
| Depreciation and amortization | $344.0K | $169.0K |
| Stock-based compensation | $13.6M | $5.9M |
| Accretion of available-for-sale investments, net | -$690.0K | $0 |
| Change in fair value of derivative liability | $9.5M | $2.9M |
| Acquired in-process research and development | $0 | $27.6M |
| Excess of initial warrant fair value over private placement proceeds | $0 | $79.3M |
| Change in fair value of warrant liability | $0 | -$121.6M |
| Transaction costs paid pursuant to private placement | $0 | $7.5M |
| Transaction costs paid upon exercise of warrants issued in private placement | $0 | $1.7M |
| Contingent consideration paid pursuant to AlmataBio Transaction | $0 | -$12.5M |
| Lease early termination fee | $0 | -$309.0K |
| Deferred taxes | $165.0K | $114.0K |
| Other receivables | $0 | -$475.0K |
| Prepaid expenses and other assets | -$2.6M | -$2.9M |
| Accounts payable | -$146.0K | -$163.0K |
| Accrued expenses and other liabilities, excluding lease liability | $6.7M | -$1.1M |
| Lease liability, net | -$87.0K | -$88.0K |
| Net cash used in operating activities | -$51.5M | -$49.1M |
| Purchase of investments | -$113.7M | $0 |
| Maturities of investments | $32.0M | $0 |
| Cash assumed from AlmataBio Transaction | $0 | $356.0K |
| Net cash (used in) provided by investing activities | -$81.7M | $356.0K |
| Proceeds from sale of common stock pursuant to ATM Program | $14.8M | $0 |
| Transaction costs paid pursuant to ATM Program | -$462.0K | $0 |
| Proceeds from exercise of stock options | $774.0K | $0 |
| Proceeds from issuance of common stock under employee stock purchase plan, net of cash paid related to withholding shares to satisfy tax withholding obligations | $23.0K | $68.0K |
| Cash paid related to withholding shares to satisfy RSU tax withholding obligations | -$510.0K | $0 |
| Proceeds from private placement investment, gross | $0 | $115.6M |
| Transaction costs paid pursuant to private placement | $0 | -$7.5M |
| Proceeds from exercise of warrants issued in private placement, gross | $0 | $69.4M |
| Transaction costs paid upon exercise of warrants issued in private placement | $0 | -$1.7M |
| Net cash provided by financing activities | $14.6M | $175.8M |
| (Decrease) increase in cash, cash equivalents, and restricted cash | -$118.6M | $127.1M |
| Issuance of common stock and Series C Preferred Stock pursuant to AlmataBio Transaction | $0 | $12.3M |
| Remeasurement of lease | $0 | -$312.0K |
Timeline
Links
- Websitewww.avantium.com1
- WikidataQ30254917
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataAvantium on Wikidata
- 2SEC EDGARAvantium 10-K for fiscal 2025
- 3SEC EDGARAvantium 10-K for fiscal 2019
- 4SEC EDGARAvantium 10-K for fiscal 2020
- 5SEC EDGARAvantium 10-K for fiscal 2021
- 6SEC EDGARAvantium 10-K for fiscal 2022
- 7SEC EDGARAvantium 10-K for fiscal 2023
- 8SEC EDGARAvantium 10-Q for fiscal 2026
- 9SEC EDGARAvantium 10-Q for fiscal 2026